Wall Street Says Hair Loss Is the Next Ozempic... I Found the Stock to Watch

Wall Street thinks it may have found the next Ozmpic. Except this one isn't for weight loss. It's for baldness. Now, there hasn't been a new FDA approved drug for pattern hair loss in America in nearly 30 years. But right now, one company is racing to change that. It already has a pill that grew more than four times as much hair as the placebo in a major human trial. And the stock is soaring. And think about who the customer is here. 50 million American men, 30 million American women. And every single one of them pays cash. No insurance company, no prior authorization, nobody deciding whether they're allowed to have it. That is 80 million people standing there with a credit card and a problem that has had no good solution for three decades. Today, I'm going to show you the company, the date that decides it, and why I think this could be the next hot pharmaceutical stock. Make sure to subscribe to the channel. That way, as usual, I will do my best to keep you two steps ahead of Wall Street. Now, first things first, why has nobody solved this? The FDA has approved exactly two drugs for pattern hair loss. Minoxidil in 1988, finasteride in 1997. That's it. That's the entire list. And both of them were accidents. Minoxidil was a blood pressure medication. Finasteride was a prostate drug. Doctors just happened to notice their patients growing hair as a side effect and worked backwards. But nobody set out to cure baldness. They tripped over it twice. And then for 29 years, nothing else has come. Big pharma walked away from this. Merc, Fizer, Johnson and Johnson. None of them have a program. They instead chased cancer and cholesterol and obesity, which okay, maybe that was the right move. But they left 80 million cash paying customers sitting at the table with nothing. So, a small company picked it up. And that company is Verodmix, ticker M. Yes, that spells Maine. And yes, sometimes these companies get cute with their ticker symbol. Anyway, now what they did is take minoxidil, the drug that works best to be rubbed on your scalp twice a day forever. And they put it in a time releaseleas pill. And on April 27th, they published the result. 33 new hairs per square centimeter. The placebo group grew seven. So more than four times the control group, and the odds that being random are less than one in 10,000. So both primary goals of the trial were hit. This is not a maybe. This is a drug and an easily marketable one. Folks, the demand is already there before this thing's even approved. They don't have to go out and create a market. They don't need to run commercials during Dancing with the Stars to convince me that, hey, maybe I do in fact have mild to severe rheumatoid arthritis. Doctors have been writing the old version of this pill off label, meaning for use to the FDA, never signed off on about three million times a year. And look at how fast that's moving. 18,000 doctors riding it in 2022, 32,000 the next year, 46,000 the year after that, and nobody ran any commercials. There's no sales force. There's no ad budget because you can't advertise a generic drug. That growth is pure word of mouth, and it is still only reaching about half of a percent of the people who have this condition. Now, before I get into the second half of the story, listen, I would love to help you. I want to teach you how to properly invest in trade stocks. And for $5 a year, I'll do that. Now, I've got my Black Ops membership going on, that same YouTube special where every single week for a year, you, me, and the other members get together live in an interactive format for an hour. We review the stock market, the leading groups, the leading stocks. I'll show you the patterns that predict stocks that have a good chance of making a big move. I'll show you how to rotate out, when to sell, tactics. We'll look at your stocks. Nothing's off limits. All for just five bucks for the whole year. No strings. I'll throw in my weekly email email newsletter. I'll toss in our indicators, even some bonus reports. All of it yours just five bucks, no strings. So, click the link in the description, scan the QR code in the corner. Just go to tradewithro.com to get signed up and let's start working together. Okay, back to the story. Now, roughly 5 million Americans use the over-the-counter topical version every year, and 86% of them quit inside of 12 months. Now, to be clear, they're not quitting because the drug doesn't work. They're quitting because rubbing foam into your scalp twice a day for the rest of your life is miserable. So that is four million people a year who want this fixed, already tried, already spent money and walked away frustrated. Well, the pill doesn't have to convince them of anything. It's just a pill. It just has to exist. They'll take it. And then there's the half of this market nobody talks about. 30 million American women have patterned hair loss and there has never been an approved pill for them. Not one in the entire history of medicine. Finasteride is approved for men only. Can't be given to women who might get pregnant. The only approved option a woman has is that same foam. You think men hate losing their hair? Don't you think women hate it? And Veradermix ran a trial in women this summer. Nine out of 10 reported their hair approved. If this thing gets approved specifically for women, they're not competing for market share. They are the market. There's nothing else on the shelf. Now, before you run out and buy this stock, let me tell you about the other stock in this space, cuz Wall Street's pushing it hard, and I want you to know what it is you'd be buying. The other company is Absky. At least I think that's how you pronounce it. But the ticker is ABSI. Now, I actually traded this stock a couple years ago. It was a recommendation to my members on a breakout, as you can see, and it worked. It more than doubled in like two weeks, and this stock is on the move again, up more than 300% this year on hair loss drug. Eli Liy put money into the company. 10 analysts cover it. But here's the thing. Their drug has never grown a hair on a human being. Not one strand. Everything published so far, and I have checked, I double checked, I had Claude checked, everything published so far is safety data from 32 healthy volunteers. The company's own annual report said the drug's effects, and I quote, have not been demonstrated in any clinical studies to date. That's their words. Now it might work. I hope it does. I hope every investor gets rich. But right now, this one is a bit of a lottery ticket trade. It is going to either win big or it is going to fail big. Verodermics, on the other hand, is a business with data, with proof. But over the last 60 days, the stock is down. But the reason has nothing to do with the drug. You see, when a company goes public, insiders can't sell for 180 days. Well, Verodermics went public. had IPOed on February the 3rd and that 180day clock ran out on August 2nd when 20 million shares came free and the early backers started taking profits as they do. But this is a supply story, not a science story, not a drugs not working. The stocks down and it has nothing to do with the drug. Nothing has changed. In fact, let's go ahead and take a look at the chart. So this is Maine M. As you can see, this chart starts here in February when it went public. And unlike most IPOs that kind of jump in the first couple of weeks on hype, get absolutely clobbered in price discovery base around here and start moving, this thing just came out of the gate running. Never pulled back, never slowed down from 30 bucks to 130 in about four months. And then here in August, the lockup expiration happens. We've seen some selling pressure, but all in all, the stocks actually held up pretty well. And if you come back here and you look at previous draw downs, uh this is I mean while the thing was running before any lockup was about a 27% dip. So we've seen here July and August is right about in that same range 25 30%. Nothing crazy. Okay. So it's a little better price than it was back in July. It's a little worse than it was when it went public, but the trajectory of the stock is very clear. And that brings us to the big date. There is a second phase three trial in men. This is a confirming study and the results are going to come out before the end of this year. Then the women's trial comes out in the first half of 2027. And if the confirming trial matches, what we already saw in April, this company files with the FDA and becomes the first new hair loss drug in a generation. Now the company right now is a market cap of around $4 billion. So it's not a little penny stock, but it's not Fizer either. Now, should it be worth two billion? Should it be worth 20 billion? I don't know. It's kind of tough to price a company with no sales, with a huge new market, we're trying to figure out what it's going to be worth, but their financial position is good. They're sitting on $820 million in cash. Uh, so they are funded all the way into 2030. They don't need to raise any money. And the Wall Street analysts have an average price target of around $163 a share, which is what, 70 80% above the current price. Now, if the women's trial hits, that number is going to look conservative because almost nobody is modeling those 30 million customers who currently have zero options. But look, this is in no way a sure thing. The generic version of this molecule is cheap. That is a real competitive question. But again, generics don't run commercials. Generics aren't marketed to 46,000 prescribers by professional sales force. And generics are not approved for the 30 million women who make up nearly half this market. 29 years of nothing. 80 million people paying cash and one company with the data and a balance sheet to take it. What's it worth today? I have no idea. There hasn't been a hair loss drug in a generation. There's plenty of variables. But this could be huge. And if it is, I want to own it before the trial results go public, not after. Folks, again, don't forget to subscribe to the channel and join my Black Ops trading service. It is five bucks. I promise you'll get a hundred times the value. If you don't, call me, shoot me your email. I'll put five bucks in the mail for you. Otherwise, I'll see you in the next